[1]叶桢 孙丽杰 李忠衡.1型心肾综合征的发病机制与生物标志物研究进展[J].心血管病学进展,2024,(5):385.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.001]
　YE Zhen,SUN Lijie,LI Zhongheng.Pathogenesis and Biomarkers for Type 1 Cardiorenal Syndrome[J].Advances in Cardiovascular Diseases,2024,(5):385.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.001]
点击复制

1型心肾综合征的发病机制与生物标志物研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年5期
页码:
385
栏目:
综述
出版日期:
2024-05-25

文章信息/Info

Title:
Pathogenesis and Biomarkers for Type 1 Cardiorenal Syndrome
作者:
叶桢1 孙丽杰2 李忠衡2
(1.北京大学医学部,北京 100191;2.北京大学第三医院心内科 卫生部心血管分子生物学与调节肽重点实验室,北京 100191)
Author(s):
YE Zhen1; SUN Lijie2; LI Zhongheng2
(1.Peking University Health Science Center,Beijing 100191,China;2. Department of Cardiology,Peking University Third Hospital,NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides,Beijing 100191,China)
关键词:
1型心肾综合征急性心力衰竭发病机制生物标志物
Keywords:
Type 1 cardiorenal syndrome; Acute heart failure; Pathogenesis; Biomarker
DOI:
10.16806/j.cnki.issn.1004-3934.2024.05.001
摘要:
1型心肾综合征（CRS-1）是指急性心力衰竭（AHF）引起肾功能恶化，是AHF预后较差的常见并发症。目前对于CRS-1发病机制及早期诊断的了解还不足，CRS-1的发病机制主要与血流动力学改变、神经激素激活、炎症反应和氧化应激相关，而早期诊断CRS-1的生物标志物已经拓展到除肌酐外的肾脏、心脏炎症标志物等。综述CRS-1发病机制与生物标志物的研究进展，有助于指导下一步的研究来早期诊断CRS-1，改善AHF预后。
Abstract:
Type 1 cardiorenal syndrome(CRS-1) is a common complication of acute heart failure(AHF) with a poor prognosis,as AHF causes the worsening of renal function. Current understanding of the pathogenesis and early diagnosis of CRS-1 is inadequate. The pathogenesis of CRS-1 is mainly associated with hemodynamic alterations,neurohormonal activation,inflammatory response and oxidative stress,while biomarkers for early diagnosis of CRS-1 have been expanded to include renal,cardiac,and inflammatory markers in addition to creatinine. This article reviews the research progress of CRS-1 pathogenesis and biomarkers,which can help guide the further research to diagnose CRS-1 early and improve the prognosis of AHF

参考文献/References:

[1]Nohria A,Hasselblad V,Stebbins A,et al. Cardiorenal interactions:insights from the ESCAPE trial[J]. J Am Coll Cardiol,2008,51(13):1268-1274.

[2]Mullens W,Abrahams Z,Francis GS,et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure[J]. J Am Coll Cardiol,2009,53(7):589-596.
[3]Rubio-Gracia J,Giménez-López I,Sánchez-Marteles M,et al. Intra-abdominal pressure and its relationship with markers of congestion in patients admitted for acute decompensated heart failure[J]. Heart Vessels,2020,35(11):1545-1556.
[4]Uthoff H,Breidthardt T,Klima T,et al. Central venous pressure and impaired renal function in patients with acute heart failure[J]. Eur J Heart Fail,2011,13(4): 432-439.
[5]Virzì GM,Torregrossa R,Cruz DN,et al. Cardiorenal syndrome type 1 may be immunologically mediated:a pilot evaluation of monocyte apoptosis[J]. Cardiorenal Med,2012,2(1):33-42.
[6]Breglia A,Virzì GM,Pastori S,et al. Determinants of monocyte apoptosis in cardiorenal syndrome type 1[J]. Cardiorenal Med,2018,8(3):208-216.
[7]Virzì GM,de Cal M,Day S,et al. Pro-apoptotic effects of plasma from patients with cardiorenal syndrome on human tubular cells[J]. Am J Nephrol,2015,41(6):474-484.
[8] Virzì GM,Clementi A,de Cal M,et al. Oxidative stress:dual pathway induction in cardiorenal syndrome type 1 pathogenesis[J]. Oxid Med Cell Longev,2015,2015:391790.
[9]Bock JS,Gottlieb SS. Cardiorenal syndrome:new perspectives[J]. Circulation,2010,121(23):2592–2600.
[10] Mitsas AC,Elzawawi M,Mavrogeni S,et al. Heart failure and cardiorenal syndrome:a narrative review on pathophysiology,diagnostic and therapeutic regimens-from a cardiologist’s view[J]. J Clin Med,2022,11(23):7041.
[11] Ferrari F,Scalzotto E,Esposito P,et al. Neutrophil gelatinase-associated lipocalin does not predict acute kidney injury in heart failure[J]. World J Clin Cases,2020,8(9):1600-1607.
[12] Atici A,Emet S,Toprak ID,et al. The role of kidney injury molecule-1 in predicting cardiorenal syndrome type 1 after diuretic treatment[J]. Arch Med Sci Atheroscler Dis,2019,4: e208-e214.
[13] Ahmad T,Jackson K,Rao VS,et al. Worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury[J]. Circulation,2018,137(19):2016-2028.
[14] Takahama H,Nishikimi T,Takashio S,et al. Change in the NT-proBNP/mature BNP molar ratio precedes worsening renal function in patients with acute heart failure:a novel predictor candidate for cardiorenal syndrome[J]. J Am Heart Assoc,2019,8(17):e011468.
[15] Linhart C,Ulrich C,Greinert D,et al. Systemic inflammation in acute cardiorenal syndrome:an observational pilot study[J]. ESC Heart Fail,2018,5(5):920-930.
[16] Virzì GM,Breglia A,Brocca A,et al. Levels of proinflammatory cytokines,oxidative stress,and tissue damage markers in patients with acute heart failure with and without cardiorenal syndrome type 1[J]. Cardiorenal Med,2018,8(4):321-331.
[17] Virzì GM,Breglia A,Ankawi G,et al. Plasma lipopolysaccharide concentrations in cardiorenal syndrome type 1[J]. Cardiorenal Med,2019,9(5):308-315.
[18] Virzì GM,Breglia A,Castellani C,et al. Lipopolysaccharide in systemic circulation induces activation of inflammatory response and oxidative stress in cardiorenal syndrome type 1[J]. J Nephrol,2019,32(5):803-810.
[19] Zhang DQ,Li HW,Chen HP,et al. Combination of amino-terminal pro-BNP,estimated GFR,and high-sensitivity CRP for predicting cardiorenal syndrome type 1 in acute myocardial infarction patients[J]. J Am Heart Assoc,2018,7(19):e009162.
[20] Phan Thai H,Hoang Bui B,Hoang Anh T,et al. Value of plasma NGAL and creatinine on first day of admission in the diagnosis of cardiorenal syndrome type 1[J]. Cardiol Res Pract,2020,2020:2789410.
[21] Zhao HL,Hu HJ,Zhao XJ,et al. Urine N-terminal pro-B-type natriuretic peptide and plasma proenkephalin are promising biomarkers for early diagnosis of cardiorenal syndrome type 1 in acute decompensated heart failure:a prospective,double-center,observational study in real-world[J]. Ren Fail,2022,44(1):1486-1497.
[22] Song X,Cai D,Zhang B. Clinical values of serum NGAL combined with NT-proBNP in the early prognosis of type 1 cardiorenal syndrome[J]. Am J Transl Res,2021,13(4): 3363-3368.
[23] Fan Z,Li Y,Ji H,et al. Nomogram model to predict cardiorenal syndrome type 1 in patients with acute heart failure[J]. Kidney Blood Press Res,2018,43(6):1832-1841.
[24] ?kal B,?can ?,Omaygen?MO,et al. Value of renal vascular doppler sonography in cardiorenal syndrome type 1[J]. J Ultrasound Med,2021,40(2):321-330.
[25] Aronson D,Darawsha W,Promyslovsky M,et al. Hyponatraemia predicts the acute (type 1) cardio-renal syndrome[J]. Eur J Heart Fail,2014,16(1):49-55.
[26] Virzì GM,Clementi A,Milan Manani S,et al. The role of cell-free plasma DNA in patients with cardiorenal syndrome type 1[J]. Cardiorenal Med,2021,11(5-6):218-225.
[27] Caravaca Perez P,González-Juanatey JR,Nuche J,et al. Renal function impact in the prognostic value of galectin-3 in acute heart failure[J]. Front Cardiovasc Med,2022,9:861651.
[28] Dankova M,Minarikova Z,Danko J,et al. Novel biomarkers for prediction of acute kidney injury in acute heart failure[J]. Bratisl Lek Listy,2020,121(5):321-324.

备注/Memo

备注/Memo:
基金项目：2021年北京市慢性病防治与健康教育科研项目（BJMB0012021025009）
更新日期/Last Update: 2024-06-28